Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis.
Sarah KelliherLuisa WeissSarah CullivanEllen O'RourkeClaire A MurphyShane ToolanÁine LennonPaulina B SzklannaShane P ComerHayley MacleodAna Le ChevillierSean GaineKate M A O'ReillyBrian McCullaghJohn StackPatricia B MaguireFionnuala Ní ÁinleBarry KevanePublished in: Journal of thrombosis and haemostasis : JTH (2022)
Collectively, these data demonstrate that COVID-19 of moderate severity is associated with increased plasma thrombin generation and endothelial damage, and that hypercoagulability persists despite standard LMWH thromboprophylaxis. These findings may be of clinical interest given recent clinical trial data which suggest escalated heparin dosing in non-severe COVID-19 may be associated with improved clinical outcomes.